NPPB wt Allele clinical trials
13 active trials name this biomarker in their eligibility criteria. Describe your situation to see which ones you may be eligible for.
- The STOP-MED CTRCD Trial
- Beta-blocker Discontinuation in Heart Failure With Preserved Ejection Fraction
- A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
- Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
- Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction
- A Multi-center, National, Open-label, Prospective Study to Evaluate the Performance of the V-Lap™ System
- Rural Community Peer Partnerships for Improving Methamphetamine-Associated Heart Failure Screening and Engagement
- In Search of Best Practices for Patients With Heart Failure and Secondary Mitral Regurgitation: An Evaluation of the Inova Heart Failure Treatment Algorithm
- HF2 Registry - Hemodynamic Frontiers in Heart Failure Registry
- Biomechanical Precision Medicine Registry for Patients With and Without Heart Failure
- Muscle Blood Flow Regulation in HFpEF
- The GUARDIAN Trial - Vasopressor Sub-Study
- The PEERLESS II Study
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that name “NPPB wt Allele” in their eligibility criteria, at any level. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.